The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab
The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF o...
Uloženo v:
| Vydáno v: | European journal of cancer (1990) Ročník 44; číslo 7; s. 912 - 920 |
|---|---|
| Hlavní autoři: | , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Oxford
Elsevier Ltd
01.05.2008
Elsevier |
| Témata: | |
| ISSN: | 0959-8049, 1879-0852 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC).
This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced. |
|---|---|
| AbstractList | The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced.The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced. Abstract The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced. The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced. The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of angiogenesis, is associated with poor prognosis in breast cancer. As a result, several therapeutic agents that inhibit the actions of VEGF or its receptors are currently in development for use in metastatic breast cancer (MBC). This review describes the function of VEGF in normal and tumour angiogenesis, explores the rationale behind the use of anti-VEGF therapy in MBC and details the therapeutic impact of such agents on tumour vasculature. Clinical data from trials of anti-VEGF agents in MBC are discussed, with a particular focus on the efficacy and safety of bevacizumab, the anti-VEGF agent at the most advanced stage of development in this tumour type. Future potential uses of bevacizumab in breast cancer are introduced. |
| Author | Pivot, Xavier Marty, Michel |
| Author_xml | – sequence: 1 givenname: Michel surname: Marty fullname: Marty, Michel email: m.marty@sls.aphp.fr organization: Centre for Therapeutic Innovations in Oncology and Haematology, Saint Louis University Hospital, 1 Avenue Claude Vellefaux, 75010 Paris, France – sequence: 2 givenname: Xavier surname: Pivot fullname: Pivot, Xavier organization: Department of Oncology, University Hospital J. Minjoz, Besancon, France |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20329470$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18396037$$D View this record in MEDLINE/PubMed https://inserm.hal.science/inserm-00483411$$DView record in HAL |
| BookMark | eNqFksFuEzEQhleoiKaFF-CAfIFTN4x3vVlvhZCqCihSJA6Us-X1jhOHjR1sb0p4IJ4TbxNyqEQ52Rp__4z1z3-WnVhnMcteUphSoLO3qymulJwWAHwKdApQPckmlNdNDrwqTrIJNFWTc2DNaXYWwgoAas7gWXZKednMoKwn2e_bJZKNi2ijkT1xmsh0y7cyqKGXnqDtXFxiPz4uvLuLS6Klis6TVPVysyPGkjVGGaKMRpHWY7oSJa1Cf0mue2ONSlr8uUFvMFXJnUlN7qdIuzBugYkgMh0xXBDt1BCMXRBnSYtbqcyvYS3b59lTLfuALw7nefbt44fb65t8_uXT5-urea6qoo5519IGaaWbppKsA1BVrVhTY6VbNmtYK0stkbZMdx0URccZp7rVXJe8wjbVy_PsYt93KXux8WYt_U44acTN1VwYG9CvBQDjJaN0SxP-Zo9vvPsxYIhibYLCvpcW3RDErKEVMFYn8NUBHNo1dsfWfxeRgNcHIDkve-2TgSYcuQLKomE1JI7vOeVdCB61UGZ03tnopekFBTFmQ6zEmA0xZkMATX-ukrR4ID3-4jHRu70Ik-tbg14Edb_GznhUUXTOPC5__0CuDon4jjsMKzd4m_YpqAiFAPF1TOwYWOAprFCNDl_-u8H_pv8BKTD-CQ |
| CitedBy_id | crossref_primary_10_1007_s12282_012_0344_3 crossref_primary_10_1002_cam4_3 crossref_primary_10_1155_2011_469135 crossref_primary_10_1007_s10585_011_9428_2 crossref_primary_10_1080_14712598_2017_1289171 crossref_primary_10_1186_s12885_020_6674_1 crossref_primary_10_1016_j_ctrv_2011_04_003 crossref_primary_10_1586_14737140_8_10_1559 crossref_primary_10_1007_s13277_014_1635_4 crossref_primary_10_1200_JCO_2008_21_6457 crossref_primary_10_2217_fon_09_112 crossref_primary_10_3390_nu14010079 crossref_primary_10_1039_D4NR01861C crossref_primary_10_1097_CAD_0b013e32832b2ea0 crossref_primary_10_1179_his_2010_33_1_15 crossref_primary_10_1007_s10549_013_2552_8 crossref_primary_10_2165_11207720_000000000_00000 crossref_primary_10_1016_j_prp_2023_154917 crossref_primary_10_1016_j_ctrv_2009_10_001 crossref_primary_10_1038_nrc2442 crossref_primary_10_1158_0008_5472_CAN_09_4373 crossref_primary_10_4137_BCBCR_S6562 crossref_primary_10_1093_annonc_mdq122 crossref_primary_10_1111_j_1365_2613_2010_00748_x crossref_primary_10_1002_14651858_CD008941_pub2 crossref_primary_10_1186_1756_0500_5_162 crossref_primary_10_3109_02713683_2014_943910 crossref_primary_10_1007_s10147_012_0421_9 crossref_primary_10_1007_s00701_022_05348_x crossref_primary_10_1158_1078_0432_CCR_11_3376 crossref_primary_10_1634_theoncologist_2010_0271 crossref_primary_10_1007_s12094_009_0368_0 crossref_primary_10_1111_j_1349_7006_2009_01222_x crossref_primary_10_2147_NDT_S368740 crossref_primary_10_1007_s13277_014_2799_7 crossref_primary_10_1186_1471_2407_12_482 crossref_primary_10_1016_j_nucmedbio_2011_10_020 crossref_primary_10_1007_s00262_009_0719_2 crossref_primary_10_1007_s12253_011_9413_8 crossref_primary_10_1097_CCO_0b013e328312efba crossref_primary_10_1515_HMBCI_2010_058 |
| Cites_doi | 10.1016/S0021-9258(18)99049-6 10.1016/0006-291X(92)90483-2 10.1158/1078-0432.CCR-05-2603 10.1038/nm988 10.1158/0008-5472.CAN-03-3986 10.1056/NEJMoa072113 10.1172/JCI117858 10.1200/JCO.1999.17.8.2341 10.1074/jbc.270.34.19761 10.1038/nrc1093 10.1038/sj.bjc.6601005 10.1159/000088481 10.1016/j.gde.2004.12.005 10.1016/S1040-8428(00)00062-7 10.3816/CBC.2003.n.039 10.1182/blood.V92.11.4150 10.1126/science.1104819 10.1200/JCO.2005.03.4645 10.1053/sonc.2002.37265 10.1023/B:CLIN.0000006873.65590.68 10.1158/1078-0432.CCR-04-1923 10.1053/gast.2000.19578 10.1038/362841a0 10.1016/S1055-3207(18)30069-3 10.1053/j.seminoncol.2003.08.013 10.1200/JCO.2005.05.098 10.1126/science.1312256 10.1097/00130404-200201000-00009 10.1038/nm0901-987 10.1200/JCO.2001.19.6.1707 10.1200/JCO.2002.09.002 10.1200/JCO.2005.01.5388 10.1073/pnas.072586399 10.1093/jnci/89.2.139 10.1200/JCO.2003.04.040 10.1007/s10456-004-3149-y 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8 10.1093/jnci/dji174 10.1038/nm0603-669 10.1016/0046-8177(95)90119-1 10.1210/mend-5-12-1806 10.1200/JCO.1998.16.9.3121 10.1046/j.1523-1755.1999.00610.x 10.1016/S0002-9440(10)63273-7 10.1038/386671a0 10.1097/00000658-196609000-00012 10.1046/j.1365-2613.1998.700404.x 10.1016/S1359-6349(05)80574-9 10.1023/A:1008339408300 |
| ContentType | Journal Article |
| Copyright | 2008 Elsevier Ltd Elsevier Ltd 2008 INIST-CNRS Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2008 Elsevier Ltd – notice: Elsevier Ltd – notice: 2008 INIST-CNRS – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 1XC |
| DOI | 10.1016/j.ejca.2008.01.005 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1879-0852 |
| EndPage | 920 |
| ExternalDocumentID | oai:HAL:inserm-00483411v1 18396037 20329470 10_1016_j_ejca_2008_01_005 S0959804908000051 1_s2_0_S0959804908000051 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZGI ZXP ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AAIAV ABLVK ABYKQ AHPSJ AJBFU DOVZS LCYCR ZA5 9DU AAYXX CITATION AGCQF AGRNS IQODW CGR CUY CVF ECM EIF NPM 7X8 1XC |
| ID | FETCH-LOGICAL-c527t-db19e15f995a4d00c57c497e5fb4694ba3fae1b4fdd022d8481fbf8f385eb1b43 |
| ISICitedReferencesCount | 60 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000256673900011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0959-8049 |
| IngestDate | Tue Oct 14 20:22:02 EDT 2025 Thu Oct 02 06:26:19 EDT 2025 Thu Apr 03 07:04:28 EDT 2025 Mon Jul 21 09:10:38 EDT 2025 Sat Nov 29 04:04:09 EST 2025 Tue Nov 18 22:25:30 EST 2025 Fri Feb 23 02:16:50 EST 2024 Sun Feb 23 10:18:56 EST 2025 Tue Oct 14 19:25:00 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Angiogenesis Breast cancer Monoclonal antibody Tyrosine kinase inhibitor Vascular endothelial growth factor (VEGF) Bevacizumab Antineoplastic agent Breast disease Enzyme Transferases VEGF Pharmacology Malignant tumor Metastasis Mammary gland diseases Cancerology Vascular endothelium growth factor Treatment Advanced stage Inhibitor Neovascularization Antiangiogenic agent Protein-tyrosine kinase Vascular endothelial growth factor Cancer |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c527t-db19e15f995a4d00c57c497e5fb4694ba3fae1b4fdd022d8481fbf8f385eb1b43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 18396037 |
| PQID | 69150447 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | hal_primary_oai_HAL_inserm_00483411v1 proquest_miscellaneous_69150447 pubmed_primary_18396037 pascalfrancis_primary_20329470 crossref_citationtrail_10_1016_j_ejca_2008_01_005 crossref_primary_10_1016_j_ejca_2008_01_005 elsevier_sciencedirect_doi_10_1016_j_ejca_2008_01_005 elsevier_clinicalkeyesjournals_1_s2_0_S0959804908000051 elsevier_clinicalkey_doi_10_1016_j_ejca_2008_01_005 |
| PublicationCentury | 2000 |
| PublicationDate | 2008-05-01 |
| PublicationDateYYYYMMDD | 2008-05-01 |
| PublicationDate_xml | – month: 05 year: 2008 text: 2008-05-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: England |
| PublicationTitle | European journal of cancer (1990) |
| PublicationTitleAlternate | Eur J Cancer |
| PublicationYear | 2008 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Linderholm, Lindh, Beckman (bib36) 2003; 4 Bergers, Benjamin (bib2) 2003; 3 Ikeda, Achen, Breier, Risau (bib11) 1995; 270 Gasparini, Toi, Gion (bib33) 1997; 89 Gerwins, Skoldenberg, Claesson-Welsh (bib5) 2000; 34 Traina, Rugo, Caravelli (bib45) 2007; 25 Lyons, Silverman, Remick (bib63) 2006; 24 Cascinu, Graziano, Valentini (bib42) 2001; 12 Jassem, Pienkowski, Pluzanska (bib75) 2001; 19 Miller, Wang, Gralow (bib48) 2007; 357 Terman, Dougher-Vermazen, Carrion (bib16) 1992; 187 Baluk, Hashizume, McDonald (bib29) 2005; 15 F. Hoffmann-La Roche, data on file. Winer, Morrow, Osborne, Harris (bib1) 2001 Gordon, Cunningham (bib62) 2005; 69 2007 [accessed 27.10.2007]. Rugo, Dickler, Scott (bib60) 2005; 23 Lee, Heijn, di Tomaso (bib40) 2000; 60 Borgstrom, Hillan, Sriramarao, Ferrara (bib43) 1996; 56 Miller, Trigo, Wheeler (bib71) 2005; 11 Jain (bib23) 2001; 7 Chan, Friedrichs, Noel (bib74) 1999; 17 Nabholtz, Falkson, Campos (bib73) 2003; 21 Risau (bib14) 1997; 386 Gupta, Jaskowiak, Beckett (bib41) 2002; 8 Ince, Jubb, Holden (bib59) 2005; 97 Willett, Boucher, di Tomaso (bib26) 2004; 10 Tran, Master, Yu, Rak, Dumont, Kerbel (bib39) 2002; 99 Pegram, Chan, Dichmann (bib57) 2006; 100 Ramaswamy, Elias, Kelbick (bib51) 2006; 12 Moreno-Aspitia, Hillman, Wiesenfeld (bib70) 2006; 24 Vosseler, Mirancea, Bohlen, Mueller, Fusenig (bib31) 2005; 65 F. Hoffmann-La Roche Ltd. Avastin summary of product characteristics. Brown, Berse, Jackman (bib32) 1995; 26 Rugo, Dickler, Traina (bib61) 2006; 24 Rak, Mitsuhashi, Bayko (bib12) 1995; 55 Melemed AS, O’Shaughnessy J, Nag S, et al. Phase III study of gemcitabine plus paclitaxel compared with paclitaxel alone in patients with unresectable, locally recurrent, or metastatic breast cancer. In: Presented at 2007 Breast cancer symposium, 7–8 September 2007, San Francisco (CA) [abstract 150]. Foekens, Peters, Grebenchtchikov (bib37) 2001; 61 Jubb, Hurwitz, Bai (bib58) 2006; 24 Petit, Rak, Hung (bib10) 1997; 151 Ferrara (bib8) 1999; 56 Murray, Abrams, Long (bib67) 2003; 20 Chan, Allen, Hu (bib52) 2006; 24 Tischer, Mitchell, Hartman (bib7) 1991; 266 Traina, Rugo, Caravelli (bib55) 2006; 24 Bianchi, Loibl, Zamagni (bib69) 2005; 3 Rugo, Stopeck, Joy (bib72) 2007; 25 Yoshiji, Harris, Thorgeirsson (bib65) 1997; 57 Miller, Burstein, Elias (bib68) 2005; 23 Borgstrom, Gold, Hillan, Ferrara (bib18) 1999; 19 Ferrara, Gerber, LeCouter (bib24) 2003; 9 Tuder, Flook, Voelkel (bib9) 1995; 95 Linderholm, Lindh, Tavelin, Grankvist, Henriksson (bib35) 2000; 89 Gabrilovich, Ishida, Oyama (bib22) 1998; 92 Bouvet, Ellis, Nishizaki (bib13) 1998; 58 Jain (bib3) 2002; 29 Wildiers, Guetens, De Boeck (bib28) 2003; 88 Burstein, Spigel, Kindsvogel (bib54) 2005; 94 [accessed 14.03.08]. von Marschall, Cramer, Hocker (bib20) 2000; 119 Wedam, Low, Yang (bib64) 2006; 24 de Vries, Escobedo, Ueno, Houck, Ferrara, Williams (bib15) 1992; 255 Linderholm, Tavelin, Grankvist, Henriksson (bib34) 1998; 16 Folkman, Cole, Zimmerman (bib17) 1966; 164 Miller, Chap, Holmes (bib47) 2005; 23 Kim, Li, Winer (bib19) 1993; 362 Neufeld, Kessler, Vadasz, Gluzman-Poltorak (bib21) 2001; 10 Abrams, Murray, Pesenti (bib66) 2003; 2 Cobleigh, Langmuir, Sledge (bib46) 2003; 30 O’Shaughnessy, Miles, Vukelja (bib76) 2002; 20 Houck, Ferrara, Winer, Cachianes, Li, Leung (bib6) 1991; 5 Inai, Mancuso, Hashizume (bib25) 2004; 165 Jain (bib27) 2005; 307 Ragaz, Miller, Badve (bib38) 2004; 22 Epstein, Ayala, Tchekmedyian, Borgstrom, Pegram, Slamon (bib44) 2002; 76 Pegram, Yeon, Durna (bib56) 2004; 88 Osusky, Hallahan, Fu, Ye, Shyr, Geng (bib30) 2004; 7 Achen, Stacker (bib4) 1998; 79 Burstein, Parker, Savoie (bib53) 2002; 76 Abrams (10.1016/j.ejca.2008.01.005_bib66) 2003; 2 Gupta (10.1016/j.ejca.2008.01.005_bib41) 2002; 8 Traina (10.1016/j.ejca.2008.01.005_bib45) 2007; 25 Ferrara (10.1016/j.ejca.2008.01.005_bib8) 1999; 56 Willett (10.1016/j.ejca.2008.01.005_bib26) 2004; 10 Moreno-Aspitia (10.1016/j.ejca.2008.01.005_bib70) 2006; 24 O’Shaughnessy (10.1016/j.ejca.2008.01.005_bib76) 2002; 20 Borgstrom (10.1016/j.ejca.2008.01.005_bib18) 1999; 19 Winer (10.1016/j.ejca.2008.01.005_bib1) 2001 Tran (10.1016/j.ejca.2008.01.005_bib39) 2002; 99 Pegram (10.1016/j.ejca.2008.01.005_bib57) 2006; 100 Chan (10.1016/j.ejca.2008.01.005_bib74) 1999; 17 Jain (10.1016/j.ejca.2008.01.005_bib27) 2005; 307 Risau (10.1016/j.ejca.2008.01.005_bib14) 1997; 386 Inai (10.1016/j.ejca.2008.01.005_bib25) 2004; 165 Pegram (10.1016/j.ejca.2008.01.005_bib56) 2004; 88 Ferrara (10.1016/j.ejca.2008.01.005_bib24) 2003; 9 Borgstrom (10.1016/j.ejca.2008.01.005_bib43) 1996; 56 Jain (10.1016/j.ejca.2008.01.005_bib3) 2002; 29 Miller (10.1016/j.ejca.2008.01.005_bib47) 2005; 23 Epstein (10.1016/j.ejca.2008.01.005_bib44) 2002; 76 Wildiers (10.1016/j.ejca.2008.01.005_bib28) 2003; 88 Rugo (10.1016/j.ejca.2008.01.005_bib72) 2007; 25 Nabholtz (10.1016/j.ejca.2008.01.005_bib73) 2003; 21 Cascinu (10.1016/j.ejca.2008.01.005_bib42) 2001; 12 Bouvet (10.1016/j.ejca.2008.01.005_bib13) 1998; 58 Jassem (10.1016/j.ejca.2008.01.005_bib75) 2001; 19 Murray (10.1016/j.ejca.2008.01.005_bib67) 2003; 20 Gordon (10.1016/j.ejca.2008.01.005_bib62) 2005; 69 Jain (10.1016/j.ejca.2008.01.005_bib23) 2001; 7 Ragaz (10.1016/j.ejca.2008.01.005_bib38) 2004; 22 Tuder (10.1016/j.ejca.2008.01.005_bib9) 1995; 95 Houck (10.1016/j.ejca.2008.01.005_bib6) 1991; 5 Terman (10.1016/j.ejca.2008.01.005_bib16) 1992; 187 Rak (10.1016/j.ejca.2008.01.005_bib12) 1995; 55 Miller (10.1016/j.ejca.2008.01.005_bib48) 2007; 357 Burstein (10.1016/j.ejca.2008.01.005_bib53) 2002; 76 Folkman (10.1016/j.ejca.2008.01.005_bib17) 1966; 164 Traina (10.1016/j.ejca.2008.01.005_bib55) 2006; 24 Ikeda (10.1016/j.ejca.2008.01.005_bib11) 1995; 270 Osusky (10.1016/j.ejca.2008.01.005_bib30) 2004; 7 Cobleigh (10.1016/j.ejca.2008.01.005_bib46) 2003; 30 Rugo (10.1016/j.ejca.2008.01.005_bib60) 2005; 23 de Vries (10.1016/j.ejca.2008.01.005_bib15) 1992; 255 Burstein (10.1016/j.ejca.2008.01.005_bib54) 2005; 94 Lyons (10.1016/j.ejca.2008.01.005_bib63) 2006; 24 10.1016/j.ejca.2008.01.005_bib77 Lee (10.1016/j.ejca.2008.01.005_bib40) 2000; 60 Ince (10.1016/j.ejca.2008.01.005_bib59) 2005; 97 Brown (10.1016/j.ejca.2008.01.005_bib32) 1995; 26 Gerwins (10.1016/j.ejca.2008.01.005_bib5) 2000; 34 Gasparini (10.1016/j.ejca.2008.01.005_bib33) 1997; 89 Petit (10.1016/j.ejca.2008.01.005_bib10) 1997; 151 von Marschall (10.1016/j.ejca.2008.01.005_bib20) 2000; 119 Gabrilovich (10.1016/j.ejca.2008.01.005_bib22) 1998; 92 Foekens (10.1016/j.ejca.2008.01.005_bib37) 2001; 61 Tischer (10.1016/j.ejca.2008.01.005_bib7) 1991; 266 Kim (10.1016/j.ejca.2008.01.005_bib19) 1993; 362 Yoshiji (10.1016/j.ejca.2008.01.005_bib65) 1997; 57 Linderholm (10.1016/j.ejca.2008.01.005_bib34) 1998; 16 Rugo (10.1016/j.ejca.2008.01.005_bib61) 2006; 24 Achen (10.1016/j.ejca.2008.01.005_bib4) 1998; 79 Ramaswamy (10.1016/j.ejca.2008.01.005_bib51) 2006; 12 Miller (10.1016/j.ejca.2008.01.005_bib71) 2005; 11 Bergers (10.1016/j.ejca.2008.01.005_bib2) 2003; 3 Jubb (10.1016/j.ejca.2008.01.005_bib58) 2006; 24 Neufeld (10.1016/j.ejca.2008.01.005_bib21) 2001; 10 10.1016/j.ejca.2008.01.005_bib49 Baluk (10.1016/j.ejca.2008.01.005_bib29) 2005; 15 Vosseler (10.1016/j.ejca.2008.01.005_bib31) 2005; 65 Wedam (10.1016/j.ejca.2008.01.005_bib64) 2006; 24 Miller (10.1016/j.ejca.2008.01.005_bib68) 2005; 23 10.1016/j.ejca.2008.01.005_bib50 Linderholm (10.1016/j.ejca.2008.01.005_bib35) 2000; 89 Linderholm (10.1016/j.ejca.2008.01.005_bib36) 2003; 4 Bianchi (10.1016/j.ejca.2008.01.005_bib69) 2005; 3 Chan (10.1016/j.ejca.2008.01.005_bib52) 2006; 24 |
| References_xml | – reference: F. Hoffmann-La Roche Ltd. Avastin summary of product characteristics. – volume: 61 start-page: 5407 year: 2001 end-page: 5414 ident: bib37 article-title: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer publication-title: Cancer Res – volume: 94 start-page: S6 year: 2005 ident: bib54 article-title: Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study publication-title: Breast Cancer Res Treat – volume: 92 start-page: 4150 year: 1998 end-page: 4166 ident: bib22 article-title: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo publication-title: Blood – volume: 255 start-page: 989 year: 1992 end-page: 991 ident: bib15 article-title: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor publication-title: Science – volume: 2 start-page: 1011 year: 2003 end-page: 1021 ident: bib66 article-title: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer publication-title: Mol Cancer Ther – reference: [accessed 14.03.08]. – volume: 24 start-page: 769 year: 2006 end-page: 777 ident: bib64 article-title: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer publication-title: J Clin Oncol – volume: 270 start-page: 19761 year: 1995 end-page: 19766 ident: bib11 article-title: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells publication-title: J Biol Chem – volume: 55 start-page: 4575 year: 1995 end-page: 4580 ident: bib12 article-title: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis publication-title: Cancer Res – volume: 24 start-page: 133S year: 2006 ident: bib63 article-title: Toxicity results and early outcome data on a randomized phase II study of docetaxel +/– bevacizumab for locally advanced, unresectable breast cancer publication-title: J Clin Oncol – volume: 24 start-page: 133S year: 2006 ident: bib55 article-title: Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) publication-title: J Clin Oncol – volume: 19 start-page: 1707 year: 2001 end-page: 1715 ident: bib75 article-title: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial publication-title: J Clin Oncol – volume: 165 start-page: 35 year: 2004 end-page: 52 ident: bib25 article-title: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts publication-title: Am J Pathol – volume: 9 start-page: 669 year: 2003 end-page: 676 ident: bib24 article-title: The biology of VEGF and its receptors publication-title: Nat Med – volume: 3 start-page: 78 year: 2005 ident: bib69 article-title: A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer publication-title: Eur J Cancer Suppl – volume: 24 start-page: 130S year: 2006 ident: bib61 article-title: Change in circulating endothelial cells (CECs) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B) publication-title: J Clin Oncol – volume: 56 start-page: 4032 year: 1996 end-page: 4039 ident: bib43 article-title: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy publication-title: Cancer Res – volume: 57 start-page: 3924 year: 1997 end-page: 3928 ident: bib65 article-title: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells publication-title: Cancer Res – volume: 34 start-page: 185 year: 2000 end-page: 194 ident: bib5 article-title: Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis publication-title: Crit Rev Oncol Hematol – volume: 20 start-page: 2812 year: 2002 end-page: 2823 ident: bib76 article-title: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results publication-title: J Clin Oncol – volume: 11 start-page: 3369 year: 2005 end-page: 3376 ident: bib71 article-title: A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer publication-title: Clin Cancer Res – volume: 266 start-page: 11947 year: 1991 end-page: 11954 ident: bib7 article-title: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing publication-title: J Biol Chem – volume: 151 start-page: 1523 year: 1997 end-page: 1530 ident: bib10 article-title: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors publication-title: Am J Pathol – volume: 30 start-page: 117 year: 2003 end-page: 124 ident: bib46 article-title: A phase I/II dose–escalation trial of bevacizumab in previously treated metastatic breast cancer publication-title: Semin Oncol – volume: 76 start-page: S143 year: 2002 ident: bib44 article-title: HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF) publication-title: Breast Cancer Res Treat – volume: 17 start-page: 2341 year: 1999 end-page: 2354 ident: bib74 article-title: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer publication-title: J Clin Oncol – volume: 357 start-page: 2666 year: 2007 end-page: 2676 ident: bib48 article-title: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100) publication-title: N Engl J Med – volume: 20 start-page: 757 year: 2003 end-page: 766 ident: bib67 article-title: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model publication-title: Clin Exp Metastasis – volume: 100 start-page: S28 year: 2006 ident: bib57 article-title: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer publication-title: Breast Cancer Res Treat – volume: 79 start-page: 255 year: 1998 end-page: 265 ident: bib4 article-title: The vascular endothelial growth factor family; proteins which guide the development of the vasculature publication-title: Int J Exp Pathol – volume: 21 start-page: 968 year: 2003 end-page: 975 ident: bib73 article-title: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial publication-title: J Clin Oncol – volume: 187 start-page: 1579 year: 1992 end-page: 1586 ident: bib16 article-title: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor publication-title: Biochem Biophys Res Commun – volume: 8 start-page: 47 year: 2002 end-page: 54 ident: bib41 article-title: Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance publication-title: Cancer J – volume: 65 start-page: 1294 year: 2005 end-page: 1305 ident: bib31 article-title: Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants publication-title: Cancer Res – volume: 76 start-page: S115 year: 2002 ident: bib53 article-title: Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer publication-title: Breast Cancer Res Treat – volume: 89 start-page: 51 year: 2000 end-page: 62 ident: bib35 article-title: p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma publication-title: Int J Cancer – volume: 24 start-page: 22S year: 2006 ident: bib70 article-title: BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane publication-title: J Clin Oncol – volume: 12 start-page: 239 year: 2001 end-page: 244 ident: bib42 article-title: Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy publication-title: Ann Oncol – volume: 23 start-page: 19S year: 2005 ident: bib68 article-title: Phase II study of SU 11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) publication-title: J Clin Oncol – reference: Melemed AS, O’Shaughnessy J, Nag S, et al. Phase III study of gemcitabine plus paclitaxel compared with paclitaxel alone in patients with unresectable, locally recurrent, or metastatic breast cancer. In: Presented at 2007 Breast cancer symposium, 7–8 September 2007, San Francisco (CA) [abstract 150]. – volume: 4 start-page: 340 year: 2003 end-page: 347 ident: bib36 article-title: Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers publication-title: Clin Breast Cancer – volume: 25 start-page: 44S year: 2007 ident: bib45 article-title: Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model publication-title: J Clin Oncol – volume: 10 start-page: 339 year: 2001 end-page: 356 ident: bib21 article-title: The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors publication-title: Surg Oncol Clin N Am – reference: F. Hoffmann-La Roche, data on file. – volume: 26 start-page: 86 year: 1995 end-page: 91 ident: bib32 article-title: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer publication-title: Hum Pathol – volume: 12 start-page: 3124 year: 2006 end-page: 3129 ident: bib51 article-title: Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients publication-title: Clin Cancer Res – volume: 164 start-page: 491 year: 1966 end-page: 502 ident: bib17 article-title: Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment publication-title: Ann Surg – volume: 362 start-page: 841 year: 1993 end-page: 844 ident: bib19 article-title: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo publication-title: Nature – volume: 23 start-page: 10S year: 2005 ident: bib60 article-title: Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation publication-title: J Clin Oncol – volume: 7 start-page: 225 year: 2004 end-page: 233 ident: bib30 article-title: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels publication-title: Angiogenesis – volume: 5 start-page: 1806 year: 1991 end-page: 1814 ident: bib6 article-title: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA publication-title: Mol Endocrinol – volume: 97 start-page: 981 year: 2005 end-page: 989 ident: bib59 article-title: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab publication-title: J Natl Cancer Inst – volume: 29 start-page: 3 year: 2002 end-page: 9 ident: bib3 article-title: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor publication-title: Semin Oncol – start-page: 651 year: 2001 end-page: 717 ident: bib1 article-title: Malignant tumors of the breast publication-title: Cancer: principles and practice of oncology – volume: 16 start-page: 3121 year: 1998 end-page: 3128 ident: bib34 article-title: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma publication-title: J Clin Oncol – volume: 99 start-page: 4349 year: 2002 end-page: 4354 ident: bib39 article-title: A role for survivin in chemoresistance of endothelial cells mediated by VEGF publication-title: Proc Natl Acad Sci USA – volume: 58 start-page: 2288 year: 1998 end-page: 2292 ident: bib13 article-title: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer publication-title: Cancer Res – volume: 88 start-page: S124 year: 2004 ident: bib56 article-title: Phase 1 combined biologic therapy of breast cancer using 2 humanized monoclonal antibodies directed against HER2 protooncogene and vascular endothelial growth factor publication-title: Breast Cancer Res Treat – volume: 95 start-page: 1798 year: 1995 end-page: 1807 ident: bib9 article-title: Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide publication-title: J Clin Invest – volume: 23 start-page: 792 year: 2005 end-page: 799 ident: bib47 article-title: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer publication-title: J Clin Oncol – volume: 60 start-page: 5565 year: 2000 end-page: 5570 ident: bib40 article-title: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions publication-title: Cancer Res – volume: 24 start-page: 217 year: 2006 end-page: 227 ident: bib58 article-title: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer publication-title: J Clin Oncol – reference: ; 2007 [accessed 27.10.2007]. – volume: 3 start-page: 401 year: 2003 end-page: 410 ident: bib2 article-title: Tumorigenesis and the angiogenic switch publication-title: Nat Rev Cancer – volume: 19 start-page: 4203 year: 1999 end-page: 4214 ident: bib18 article-title: Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin publication-title: Anticancer Res – volume: 89 start-page: 139 year: 1997 end-page: 147 ident: bib33 article-title: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma publication-title: J Natl Cancer Inst – volume: 24 start-page: 605S year: 2006 ident: bib52 article-title: Phase 2 study of docetaxel (D) plus bevacizumab (B) in Her/2 negative metastatic breast carcinoma (MBC) publication-title: J Clin Oncol – volume: 56 start-page: 794 year: 1999 end-page: 814 ident: bib8 article-title: Role of vascular endothelial growth factor in the regulation of angiogenesis publication-title: Kidney Int – volume: 10 start-page: 145 year: 2004 end-page: 147 ident: bib26 article-title: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer publication-title: Nat Med – volume: 88 start-page: 1979 year: 2003 end-page: 1986 ident: bib28 article-title: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 publication-title: Br J Cancer – volume: 69 start-page: 25 year: 2005 end-page: 33 ident: bib62 article-title: Managing patients treated with bevacizumab combination therapy publication-title: Oncology – volume: 25 start-page: 18S year: 2007 ident: bib72 article-title: A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) publication-title: J Clin Oncol – volume: 307 start-page: 58 year: 2005 end-page: 62 ident: bib27 article-title: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy publication-title: Science – volume: 22 start-page: 8S year: 2004 ident: bib38 article-title: Adverse association of expressed vascular endothelial growth factor (VEGF), Her2, Cox2, uPA and EMSY with long-term outcome of stage I–III breast cancer (BrCa). Results from the British Columbia Tissue Microarray Project publication-title: J Clin Oncol – volume: 15 start-page: 102 year: 2005 end-page: 111 ident: bib29 article-title: Cellular abnormalities of blood vessels as targets in cancer publication-title: Curr Opin Genet Dev – volume: 386 start-page: 671 year: 1997 end-page: 674 ident: bib14 article-title: Mechanisms of angiogenesis publication-title: Nature – volume: 119 start-page: 1358 year: 2000 end-page: 1372 ident: bib20 article-title: De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop publication-title: Gastroenterology – volume: 7 start-page: 987 year: 2001 end-page: 989 ident: bib23 article-title: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy publication-title: Nat Med – volume: 151 start-page: 1523 year: 1997 ident: 10.1016/j.ejca.2008.01.005_bib10 publication-title: Am J Pathol – volume: 2 start-page: 1011 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib66 article-title: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer publication-title: Mol Cancer Ther – volume: 266 start-page: 11947 year: 1991 ident: 10.1016/j.ejca.2008.01.005_bib7 article-title: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)99049-6 – volume: 187 start-page: 1579 year: 1992 ident: 10.1016/j.ejca.2008.01.005_bib16 article-title: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor publication-title: Biochem Biophys Res Commun doi: 10.1016/0006-291X(92)90483-2 – volume: 12 start-page: 3124 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib51 article-title: Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-2603 – volume: 60 start-page: 5565 year: 2000 ident: 10.1016/j.ejca.2008.01.005_bib40 article-title: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions publication-title: Cancer Res – volume: 10 start-page: 145 year: 2004 ident: 10.1016/j.ejca.2008.01.005_bib26 article-title: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer publication-title: Nat Med doi: 10.1038/nm988 – volume: 65 start-page: 1294 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib31 article-title: Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-3986 – volume: 24 start-page: 133S issue: Suppl. 18 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib55 article-title: Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC) publication-title: J Clin Oncol – ident: 10.1016/j.ejca.2008.01.005_bib49 – volume: 357 start-page: 2666 year: 2007 ident: 10.1016/j.ejca.2008.01.005_bib48 article-title: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100) publication-title: N Engl J Med doi: 10.1056/NEJMoa072113 – volume: 95 start-page: 1798 year: 1995 ident: 10.1016/j.ejca.2008.01.005_bib9 article-title: Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide publication-title: J Clin Invest doi: 10.1172/JCI117858 – volume: 23 start-page: 10S issue: Suppl. 16 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib60 article-title: Change in circulating endothelial cells (CEC) and tumor cells (CTC) in patients (pts) receiving bevacizumab and erlotinib for metastatic breast cancer (MBC) predicts stable disease at first evaluation publication-title: J Clin Oncol – volume: 17 start-page: 2341 year: 1999 ident: 10.1016/j.ejca.2008.01.005_bib74 article-title: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.8.2341 – volume: 270 start-page: 19761 year: 1995 ident: 10.1016/j.ejca.2008.01.005_bib11 article-title: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells publication-title: J Biol Chem doi: 10.1074/jbc.270.34.19761 – volume: 3 start-page: 401 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib2 article-title: Tumorigenesis and the angiogenic switch publication-title: Nat Rev Cancer doi: 10.1038/nrc1093 – volume: 88 start-page: 1979 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib28 article-title: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 publication-title: Br J Cancer doi: 10.1038/sj.bjc.6601005 – volume: 69 start-page: 25 issue: Suppl. 3 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib62 article-title: Managing patients treated with bevacizumab combination therapy publication-title: Oncology doi: 10.1159/000088481 – volume: 15 start-page: 102 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib29 article-title: Cellular abnormalities of blood vessels as targets in cancer publication-title: Curr Opin Genet Dev doi: 10.1016/j.gde.2004.12.005 – ident: 10.1016/j.ejca.2008.01.005_bib50 – volume: 34 start-page: 185 year: 2000 ident: 10.1016/j.ejca.2008.01.005_bib5 article-title: Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis publication-title: Crit Rev Oncol Hematol doi: 10.1016/S1040-8428(00)00062-7 – volume: 19 start-page: 4203 year: 1999 ident: 10.1016/j.ejca.2008.01.005_bib18 article-title: Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin publication-title: Anticancer Res – volume: 4 start-page: 340 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib36 article-title: Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers publication-title: Clin Breast Cancer doi: 10.3816/CBC.2003.n.039 – volume: 61 start-page: 5407 year: 2001 ident: 10.1016/j.ejca.2008.01.005_bib37 article-title: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer publication-title: Cancer Res – volume: 24 start-page: 133S issue: Suppl. 18 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib63 article-title: Toxicity results and early outcome data on a randomized phase II study of docetaxel +/– bevacizumab for locally advanced, unresectable breast cancer publication-title: J Clin Oncol – volume: 55 start-page: 4575 year: 1995 ident: 10.1016/j.ejca.2008.01.005_bib12 article-title: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis publication-title: Cancer Res – volume: 92 start-page: 4150 year: 1998 ident: 10.1016/j.ejca.2008.01.005_bib22 article-title: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo publication-title: Blood doi: 10.1182/blood.V92.11.4150 – volume: 76 start-page: S115 issue: Suppl. 1 year: 2002 ident: 10.1016/j.ejca.2008.01.005_bib53 article-title: Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer publication-title: Breast Cancer Res Treat – volume: 307 start-page: 58 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib27 article-title: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy publication-title: Science doi: 10.1126/science.1104819 – volume: 24 start-page: 769 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib64 article-title: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.4645 – volume: 29 start-page: 3 year: 2002 ident: 10.1016/j.ejca.2008.01.005_bib3 article-title: Tumor angiogenesis and accessibility: role of vascular endothelial growth factor publication-title: Semin Oncol doi: 10.1053/sonc.2002.37265 – volume: 20 start-page: 757 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib67 article-title: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model publication-title: Clin Exp Metastasis doi: 10.1023/B:CLIN.0000006873.65590.68 – volume: 11 start-page: 3369 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib71 article-title: A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-1923 – volume: 119 start-page: 1358 year: 2000 ident: 10.1016/j.ejca.2008.01.005_bib20 article-title: De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop publication-title: Gastroenterology doi: 10.1053/gast.2000.19578 – volume: 362 start-page: 841 year: 1993 ident: 10.1016/j.ejca.2008.01.005_bib19 article-title: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo publication-title: Nature doi: 10.1038/362841a0 – volume: 10 start-page: 339 year: 2001 ident: 10.1016/j.ejca.2008.01.005_bib21 article-title: The contribution of proangiogenic factors to the progression of malignant disease: role of vascular endothelial growth factor and its receptors publication-title: Surg Oncol Clin N Am doi: 10.1016/S1055-3207(18)30069-3 – volume: 30 start-page: 117 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib46 article-title: A phase I/II dose–escalation trial of bevacizumab in previously treated metastatic breast cancer publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2003.08.013 – volume: 23 start-page: 792 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib47 article-title: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.098 – volume: 255 start-page: 989 year: 1992 ident: 10.1016/j.ejca.2008.01.005_bib15 article-title: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor publication-title: Science doi: 10.1126/science.1312256 – volume: 8 start-page: 47 year: 2002 ident: 10.1016/j.ejca.2008.01.005_bib41 article-title: Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance publication-title: Cancer J doi: 10.1097/00130404-200201000-00009 – volume: 24 start-page: 605S issue: Suppl. 18 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib52 article-title: Phase 2 study of docetaxel (D) plus bevacizumab (B) in Her/2 negative metastatic breast carcinoma (MBC) publication-title: J Clin Oncol – volume: 7 start-page: 987 year: 2001 ident: 10.1016/j.ejca.2008.01.005_bib23 article-title: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy publication-title: Nat Med doi: 10.1038/nm0901-987 – volume: 19 start-page: 1707 year: 2001 ident: 10.1016/j.ejca.2008.01.005_bib75 article-title: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.6.1707 – volume: 23 start-page: 19S issue: Suppl. 16 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib68 article-title: Phase II study of SU 11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) publication-title: J Clin Oncol – volume: 76 start-page: S143 issue: Suppl. 1 year: 2002 ident: 10.1016/j.ejca.2008.01.005_bib44 article-title: HER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF) publication-title: Breast Cancer Res Treat – volume: 25 start-page: 44S issue: Suppl. 18 year: 2007 ident: 10.1016/j.ejca.2008.01.005_bib45 article-title: Preclinical testing of a novel regimen of capecitabine (C) in combination with bevacizumab (B) and trastuzumab (T) in a breast cancer xenograft model publication-title: J Clin Oncol – volume: 20 start-page: 2812 year: 2002 ident: 10.1016/j.ejca.2008.01.005_bib76 article-title: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results publication-title: J Clin Oncol doi: 10.1200/JCO.2002.09.002 – volume: 94 start-page: S6 issue: Suppl. 1 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib54 article-title: Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study publication-title: Breast Cancer Res Treat – volume: 57 start-page: 3924 year: 1997 ident: 10.1016/j.ejca.2008.01.005_bib65 article-title: Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells publication-title: Cancer Res – volume: 58 start-page: 2288 year: 1998 ident: 10.1016/j.ejca.2008.01.005_bib13 article-title: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer publication-title: Cancer Res – volume: 22 start-page: 8S issue: Suppl. 14 year: 2004 ident: 10.1016/j.ejca.2008.01.005_bib38 article-title: Adverse association of expressed vascular endothelial growth factor (VEGF), Her2, Cox2, uPA and EMSY with long-term outcome of stage I–III breast cancer (BrCa). Results from the British Columbia Tissue Microarray Project publication-title: J Clin Oncol – volume: 100 start-page: S28 issue: Suppl. 1 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib57 article-title: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer publication-title: Breast Cancer Res Treat – volume: 24 start-page: 217 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib58 article-title: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.5388 – volume: 99 start-page: 4349 year: 2002 ident: 10.1016/j.ejca.2008.01.005_bib39 article-title: A role for survivin in chemoresistance of endothelial cells mediated by VEGF publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.072586399 – volume: 25 start-page: 18S issue: Suppl. 18 year: 2007 ident: 10.1016/j.ejca.2008.01.005_bib72 article-title: A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) publication-title: J Clin Oncol – volume: 24 start-page: 22S issue: Suppl. 18 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib70 article-title: BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane publication-title: J Clin Oncol – volume: 89 start-page: 139 year: 1997 ident: 10.1016/j.ejca.2008.01.005_bib33 article-title: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma publication-title: J Natl Cancer Inst doi: 10.1093/jnci/89.2.139 – volume: 21 start-page: 968 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib73 article-title: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.2003.04.040 – volume: 7 start-page: 225 year: 2004 ident: 10.1016/j.ejca.2008.01.005_bib30 article-title: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels publication-title: Angiogenesis doi: 10.1007/s10456-004-3149-y – volume: 89 start-page: 51 year: 2000 ident: 10.1016/j.ejca.2008.01.005_bib35 article-title: p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.0.CO;2-8 – volume: 97 start-page: 981 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib59 article-title: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji174 – volume: 9 start-page: 669 year: 2003 ident: 10.1016/j.ejca.2008.01.005_bib24 article-title: The biology of VEGF and its receptors publication-title: Nat Med doi: 10.1038/nm0603-669 – volume: 26 start-page: 86 year: 1995 ident: 10.1016/j.ejca.2008.01.005_bib32 article-title: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer publication-title: Hum Pathol doi: 10.1016/0046-8177(95)90119-1 – volume: 5 start-page: 1806 year: 1991 ident: 10.1016/j.ejca.2008.01.005_bib6 article-title: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA publication-title: Mol Endocrinol doi: 10.1210/mend-5-12-1806 – volume: 16 start-page: 3121 year: 1998 ident: 10.1016/j.ejca.2008.01.005_bib34 article-title: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.1998.16.9.3121 – volume: 56 start-page: 4032 year: 1996 ident: 10.1016/j.ejca.2008.01.005_bib43 article-title: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy publication-title: Cancer Res – volume: 56 start-page: 794 year: 1999 ident: 10.1016/j.ejca.2008.01.005_bib8 article-title: Role of vascular endothelial growth factor in the regulation of angiogenesis publication-title: Kidney Int doi: 10.1046/j.1523-1755.1999.00610.x – volume: 165 start-page: 35 year: 2004 ident: 10.1016/j.ejca.2008.01.005_bib25 article-title: Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)63273-7 – ident: 10.1016/j.ejca.2008.01.005_bib77 – start-page: 651 year: 2001 ident: 10.1016/j.ejca.2008.01.005_bib1 article-title: Malignant tumors of the breast – volume: 24 start-page: 130S issue: Suppl. 18 year: 2006 ident: 10.1016/j.ejca.2008.01.005_bib61 article-title: Change in circulating endothelial cells (CECs) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B) publication-title: J Clin Oncol – volume: 386 start-page: 671 year: 1997 ident: 10.1016/j.ejca.2008.01.005_bib14 article-title: Mechanisms of angiogenesis publication-title: Nature doi: 10.1038/386671a0 – volume: 164 start-page: 491 year: 1966 ident: 10.1016/j.ejca.2008.01.005_bib17 article-title: Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment publication-title: Ann Surg doi: 10.1097/00000658-196609000-00012 – volume: 79 start-page: 255 year: 1998 ident: 10.1016/j.ejca.2008.01.005_bib4 article-title: The vascular endothelial growth factor family; proteins which guide the development of the vasculature publication-title: Int J Exp Pathol doi: 10.1046/j.1365-2613.1998.700404.x – volume: 3 start-page: 78 year: 2005 ident: 10.1016/j.ejca.2008.01.005_bib69 article-title: A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer publication-title: Eur J Cancer Suppl doi: 10.1016/S1359-6349(05)80574-9 – volume: 88 start-page: S124 issue: Suppl. 1 year: 2004 ident: 10.1016/j.ejca.2008.01.005_bib56 article-title: Phase 1 combined biologic therapy of breast cancer using 2 humanized monoclonal antibodies directed against HER2 protooncogene and vascular endothelial growth factor publication-title: Breast Cancer Res Treat – volume: 12 start-page: 239 year: 2001 ident: 10.1016/j.ejca.2008.01.005_bib42 article-title: Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy publication-title: Ann Oncol doi: 10.1023/A:1008339408300 |
| SSID | ssj0007840 |
| Score | 2.1592133 |
| SecondaryResourceType | review_article |
| Snippet | The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key mediator of... Abstract The importance of angiogenesis in tumour growth and development is well known. Overexpression of vascular endothelial growth factor (VEGF), the key... |
| SourceID | hal proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 912 |
| SubjectTerms | Angiogenesis Angiogenesis Inhibitors Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Anthracyclines Anthracyclines - administration & dosage Antibodies, Monoclonal Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences Breast cancer Breast Neoplasms Breast Neoplasms - drug therapy Clinical Trials, Phase III as Topic Female Hematology, Oncology and Palliative Medicine Humans Immunology Life Sciences Medical sciences Monoclonal antibody Neoplasm Metastasis Neovascularization, Pathologic Neovascularization, Pathologic - prevention & control Paclitaxel Paclitaxel - administration & dosage Pharmacology. Drug treatments Taxoids Taxoids - administration & dosage Tumors Tyrosine kinase inhibitor Vascular endothelial growth factor (VEGF) Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor A - antagonists & inhibitors |
| Title | The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0959804908000051 https://www.clinicalkey.es/playcontent/1-s2.0-S0959804908000051 https://dx.doi.org/10.1016/j.ejca.2008.01.005 https://www.ncbi.nlm.nih.gov/pubmed/18396037 https://www.proquest.com/docview/69150447 https://inserm.hal.science/inserm-00483411 |
| Volume | 44 |
| WOSCitedRecordID | wos000256673900011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-0852 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007840 issn: 0959-8049 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSEkhLhTLsMP8FQyOalTx7xN1dBAME1iSH2znMTeMnVJtabV4AfxzE_kOLaTbmPjIvESVWkdpzlffI7t7zsHoVdak4QpTgMNzjigRgOckkwHEkJleL_AgWvaFJtge3vJZML3e70fXguznLKyTM7O-Oy_mhrOgbGNdPYvzN1eFE7AZzA6HMHscPxjw8-q2rCAbKAJz64IWsapKnMjupqaLw9hDl4fuZo7AyvFanSAJ6qWRmpUZIPUsNZrQw7LVFNScuy1lKrNkuwVctCPLA-LCu7NpIE9tCSN8UBX2aJZkwCopWops-Lb4kSmV-4KuAjZ9tmkkgJvtrJmYXIffPWkf9VyRPaLZWXrKEvj7c8taCQdfdCusnmlTUdrapcriU1v6kdumznSIZStDMPcUbOtR-eN3O6ys7DrFsdb6jiTjlUbbhESd66xJSx-Nv0nzS4pacLeNbQRsZjDOLqx_X5n8qH1_ixpRLjt_TqhluUUXuzpqmBo7ciwcm_PABpyqm2FlaunQE0odHAX3XFzGLxtsXcP9VR5H9385FgaD9B3gCBuIYgrjc9BEK9AEFsIYgtB7CCIixJ3EMQWgtjC4S32AMQdALEBIL4AQGwB-AZ7-OGqxCvwe4i-vNs5GO8Grh5IkMURq4M8DbkKYw0DiqQ5IVnMMsqZinVKR5ymcqilClOq8xwi09wUitCpTvQwiSEiSenwEVovq1I9QTiKtBzxLCV5CGNUSJIc4lSpc54ypZJM9lHoDSMylyzf1GyZCs-KPBbGmK6KayjAmH00aNvMbKqYa3899PYWXgQNblsAOK9txX7VSs3dyzkXoZhHgohLgO2juG3pgmsbNP-2x9cAxvYPmWz0u9sfRVHCkHkimooUNAyXcP3Nc3BtW0RkGHHKSB-99PgV4MLMvqQsVbWYixGHWSmlrI8eW1h3jw-mbyMyZE__6WE9Q7e68eU5Wq9PF-oFupEt62J-uonW2CTZdK_vTzcyJgw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+potential+of+anti-vascular+endothelial+growth+factor+therapy+in+metastatic+breast+cancer%3A+Clinical+experience+with+anti-angiogenic+agents%2C+focusing+on+bevacizumab&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Marty%2C+Michel&rft.au=Pivot%2C+Xavier&rft.date=2008-05-01&rft.pub=Elsevier+Ltd&rft.issn=0959-8049&rft.volume=44&rft.issue=7&rft.spage=912&rft.epage=920&rft_id=info:doi/10.1016%2Fj.ejca.2008.01.005&rft.externalDocID=S0959804908000051 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09598049%2FS0959804908X00061%2Fcov150h.gif |